New drug trial aims to control serious kidney disease
NCT ID NCT07289763
Summary
This study is testing an investigational injection called SHR-2173 in adults with primary membranous nephropathy, a serious autoimmune kidney disease. The main goals are to see if the treatment is safe and if it helps patients achieve a positive response, which could mean reducing protein in the urine or improving kidney function. Researchers will enroll about 75 participants to compare different doses and monitor their health closely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General hospital of eastern theater command
RECRUITINGNanjing, Jiangsu, 210002, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.